← Leaderboards
Stephen N. Waggoner
Cincinnati Childrens Hosp Med Ctr
$9,481,800
Attributed
$12,097,122
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,097,122 · 5
By mechanism
R01$7,804,295 · 3
DP1$3,880,500 · 1
R21$412,327 · 1
Top collaborators
- Leah Claire Kottyan5 shared
- Matthew Tyson Weirauch5 shared
- Vijayakumar Velu3 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Matthew Tyson Weirauch$11,937,428
- Leah Claire Kottyan$13,264,157
- Kasper Hoebe$3,322,827
- Patricia Chandhok Fulkerson$1,262,402
- Carolyn E Rydyznski Moderbacher$108,120
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationCellsNatural Killer CellsResponseImmuneMediatingGenesMolecularImmunologicsExhibitsInfectionInflammationAntibodiesAffinityNovel VaccinesPandemic DiseaseHiv InfectionsCessation Of LifeCd4 Positive T LymphocytesMouse StrainsHiv VaccineGlobal HealthNeutralizing AntibodyPrevent
Grant awards (20)
Blocking granzyme-mediated immune suppression to enhance HIV vaccine efficacy$556,715
R01 · FY2025 · AI · contact PI
Blocking granzyme-mediated immune suppression to enhance HIV vaccine efficacy$833,010
R01 · FY2024 · AI · contact PI
Blocking granzyme-mediated immune suppression to enhance HIV vaccine efficacy$851,001
R01 · FY2023 · AI · contact PI
Targeting natural killer cells to enhance HIV vaccine responses$654,012
R01 · FY2023 · AI · contact PI
Transcription Factor Genetics in Lupus$445,741
R01 · FY2023 · AR
Targeting natural killer cells to enhance HIV vaccine responses$655,652
R01 · FY2022 · AI · contact PI
Transcription Factor Genetics in Lupus$447,941
R01 · FY2022 · AR
Targeting natural killer cells to enhance HIV vaccine responses$657,254
R01 · FY2021 · AI · contact PI
Transcription Factor Genetics in Lupus$438,893
R01 · FY2021 · AR
Genetics of organ-specific lupus disease sequelae$204,762
R21 · FY2021 · AI · contact PI
Targeting natural killer cells to enhance HIV vaccine responses$668,632
R01 · FY2020 · AI · contact PI
Transcription Factor Genetics in Lupus$448,519
R01 · FY2020 · AR
Genetics of organ-specific lupus disease sequelae$207,565
R21 · FY2020 · AI · contact PI
Targeting natural killer cells to enhance HIV vaccine responses$685,580
R01 · FY2019 · AI · contact PI
Transcription Factor Genetics in Lupus$461,345
R01 · FY2019 · AR
A revolutionary vaccine approach to prevent HIV infection in substance abuse$780,000
DP1 · FY2018 · DA · contact PI
A revolutionary vaccine approach to prevent HIV infection in substance abuse$780,000
DP1 · FY2017 · DA · contact PI
A revolutionary vaccine approach to prevent HIV infection in substance abuse$772,200
DP1 · FY2016 · DA · contact PI
A revolutionary vaccine approach to prevent HIV infection in substance abuse$768,300
DP1 · FY2015 · DA · contact PI
A revolutionary vaccine approach to prevent HIV infection in substance abuse$780,000
DP1 · FY2014 · DA · contact PI